Approved treatment for mid-term knee arthritis PRP injection...Expected to improve pain and function at Himchan Hospital
Jan 06, 2025
Amid active research on the treatment of mid-term degenerative knee arthritis, the safety and effectiveness of the injection of knee osteoarthritis autologous platelet-rich plasma (PRP)' has recently been recognized, drawing attention as a non-surgical treatment option for knee arthritis.
In December, the Ministry of Health and Welfare's New Medical Technology Evaluation Committee approved and announced 'autologous platelet-rich plasma intra-articular injection of knee osteoarthritis as a new medical technology'. The procedure method involves collecting peripheral blood and injecting self-platelet-rich plasma separated through centrifugation into the knee joint cavity.
In the case of knee arthritis, there is no special treatment other than artificial joint surgery when the cartilage is worn out and the joint bones collide with each other and the pain is severe. Therefore, in the mid-term stage, we aim to slow the progression of the disease as much as possible and improve pain and function to delay the timing of artificial joint surgery or not receive it as much as possible. For this reason, research on mid-term knee arthritis treatment has been actively conducted recently.
According to the new medical technology evaluation report, the treatment is effective in relieving pain and improving function of mid-term knee arthritis, and safety is also acceptable as no serious complications have been reported. The new medical technology evaluation system evaluates the safety and effectiveness of new medical technologies through objective evidence and expert discussions, and passing it means that it is a reliable and proven treatment.
Self-platelet-rich plasma (PRP) injection treatment collects 30mL of blood from one's own blood vessels, centrifuges it to extract concentrated PRP, and injects it into the problematic knee joint cavity through an activation process. Autologous platelet-rich plasma (PRP) has more than 1 million platelets per microliter (μL) of blood, and platelets are concentrated four to seven times higher than ordinary blood. These activated platelets play a variety of roles in treatment, including blood clotting, growth factor release, inflammatory response control, angiogenesis induction, and cell migration promotion. Therefore, PRP has been used for treatment in ophthalmology and obstetrics in addition to orthopedic surgery.
In particular, since you use your own blood, there are few side effects, and you can fundamentally improve pain and function, not temporary effects. In addition, the convenience of treatment and recovery has increased because daily life is possible immediately after the procedure on the same day without having to be hospitalized.
To increase the effectiveness of autologous platelet-rich plasma (PRP) injection therapy, it is important to increase the accuracy of extraction and the activity of concentrated PRP. This is because if other ingredients are added during extraction, side effects may occur or the treatment effect may decrease, and the more active the growth factor in the concentrate, the better the effect.
Lee Soo-chan, CEO of Himchan Hospital (Orthopedic Surgeon), is working to increase the accuracy of extraction and increase the activity of PRP by using patented equipment. When extracting by human hand, the accuracy may vary depending on the skill level, so it may be extracted more stably by using a device. It is also expected that the patented special activation device will be used to increase activity by using natural activation principles without chemical additives."
Himchan Hospital jointly researched and developed PRO ACT+ with the manufacturer, which increased the combined strength of existing special activation devices and syringes, and received permission from the Ministry of Food and Drug Safety in early 2024 to reduce the risk of loss of concentrates.
Lee Soo-chan, CEO of the company, said "Autologous platelet-rich plasma (PRP) injection treatment is a treatment with high convenience for patients because the treatment can be performed on the same day in an outpatient clinic without hospitalization. However, patients with mid-term (KL stage 2~3) arthritis who do not respond even if they have been treated with oral drugs, steroids, and hyaluronic acid injections for more than a year are eligible for treatment, and they should be treated more than 3~5 times depending on the condition of the disease."
In December, the Ministry of Health and Welfare's New Medical Technology Evaluation Committee approved and announced 'autologous platelet-rich plasma intra-articular injection of knee osteoarthritis as a new medical technology'. The procedure method involves collecting peripheral blood and injecting self-platelet-rich plasma separated through centrifugation into the knee joint cavity.
In the case of knee arthritis, there is no special treatment other than artificial joint surgery when the cartilage is worn out and the joint bones collide with each other and the pain is severe. Therefore, in the mid-term stage, we aim to slow the progression of the disease as much as possible and improve pain and function to delay the timing of artificial joint surgery or not receive it as much as possible. For this reason, research on mid-term knee arthritis treatment has been actively conducted recently.
According to the new medical technology evaluation report, the treatment is effective in relieving pain and improving function of mid-term knee arthritis, and safety is also acceptable as no serious complications have been reported. The new medical technology evaluation system evaluates the safety and effectiveness of new medical technologies through objective evidence and expert discussions, and passing it means that it is a reliable and proven treatment.
Self-platelet-rich plasma (PRP) injection treatment collects 30mL of blood from one's own blood vessels, centrifuges it to extract concentrated PRP, and injects it into the problematic knee joint cavity through an activation process. Autologous platelet-rich plasma (PRP) has more than 1 million platelets per microliter (μL) of blood, and platelets are concentrated four to seven times higher than ordinary blood. These activated platelets play a variety of roles in treatment, including blood clotting, growth factor release, inflammatory response control, angiogenesis induction, and cell migration promotion. Therefore, PRP has been used for treatment in ophthalmology and obstetrics in addition to orthopedic surgery.
In particular, since you use your own blood, there are few side effects, and you can fundamentally improve pain and function, not temporary effects. In addition, the convenience of treatment and recovery has increased because daily life is possible immediately after the procedure on the same day without having to be hospitalized.
To increase the effectiveness of autologous platelet-rich plasma (PRP) injection therapy, it is important to increase the accuracy of extraction and the activity of concentrated PRP. This is because if other ingredients are added during extraction, side effects may occur or the treatment effect may decrease, and the more active the growth factor in the concentrate, the better the effect.
Lee Soo-chan, CEO of Himchan Hospital (Orthopedic Surgeon), is working to increase the accuracy of extraction and increase the activity of PRP by using patented equipment. When extracting by human hand, the accuracy may vary depending on the skill level, so it may be extracted more stably by using a device. It is also expected that the patented special activation device will be used to increase activity by using natural activation principles without chemical additives."
Himchan Hospital jointly researched and developed PRO ACT+ with the manufacturer, which increased the combined strength of existing special activation devices and syringes, and received permission from the Ministry of Food and Drug Safety in early 2024 to reduce the risk of loss of concentrates.
Lee Soo-chan, CEO of the company, said "Autologous platelet-rich plasma (PRP) injection treatment is a treatment with high convenience for patients because the treatment can be performed on the same day in an outpatient clinic without hospitalization. However, patients with mid-term (KL stage 2~3) arthritis who do not respond even if they have been treated with oral drugs, steroids, and hyaluronic acid injections for more than a year are eligible for treatment, and they should be treated more than 3~5 times depending on the condition of the disease."
|
This article was translated by Naver AI translator.
